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A promising approach to increase the specificity of photosensitisers used in photodynamic therapy has been through conjugation to
monoclonal antibodies (MAb) directed against tumour-associated antigens. Many of the conjugations performed to date have relied
on the activated ester method, which can lead to impure conjugate preparations and antibody crosslinking. Here, we report the
development of photosensitiser–MAb conjugates utilising two porphyrin isothiocyanates. The presence of a single reactive
isothiocyanate allowed facile conjugation to MAb FSP 77 and 17.1A directed against internalising antigens, and MAb 35A7 that binds
to a non-internalising antigen. The photosensitiser–MAb conjugates substituted with 1–3mol of photosensitiser were characterised
in vitro. No appreciable loss of immunoreactivity was observed and binding specificity was comparable to that of the unconjugated
MAb. Substitution with photosensitiser had a minimal effect on antibody biodistribution in vivo for the majority of the conjugates,
although a decreased serum half-life was observed using a cationic photosensitiser at the higher loading ratios. Tumour-to-normal
tissue ratios as high as 33.5 were observed using MAb 35A7 conjugates. The internalising conjugate showed a higher level of
phototoxicity as compared with the non-internalising reagent, using a cell line engineered to express both target antigens. These data
demonstrate the applicability of the isothiocyanate group for the development of high-quality conjugates, and the use of internalising
MAb to significantly increase the photodynamic efficiency of conjugates during photoimmunotherapy.
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Photodynamic therapy (PDT) is a multicomponent anticancer
treatment that involves the administration of a photosensitising
drug and its subsequent activation by light of the appropriate
wavelength (Macdonald and Dougherty, 2001). In the field of
oncology, PDT is primarily used for the treatment of superficially
localised tumours (Dougherty et al, 1998). In this context, the area
illuminated is accessible, and treatment is associated with minimal
toxicity, favourable tumour response and a good cosmetic outcome
(Kubler et al, 1999). Photodynamic therapy has also been
investigated for the treatment of deep-seated or disseminated
malignancies (Biel, 1998); unfortunately, acute damage to surround-
ing normal tissue and treatment-related toxicity is often observed as
a consequence of poor photosensitiser selectivity, and difficulties
directing the light source to the tumour mass (Nseyo et al, 1998).
Several approaches have been investigated to increase the
specificity of photosensitisers for cancerous tissues (Brasseur et al,
1999; Gijsens et al, 2000; Swamy et al, 2002). Of considerable
interest has been the conjugation of photosensitisers to mono-
clonal antibodies (MAb) directed against tumour-associated
antigens; this approach is often termed photoimmunotherapy
(PIT). Conjugates of photosensitisers with MAb directed against a
variety of targets have been produced including oncofoetal
antigens (Carcenac et al, 1999), receptors for signal transduction
pathways (Carcenac et al, 2001) and growth factor receptors
(Hamblin et al, 2000).
A notable drawback in the development of well-characterised
photosensitiser–MAb conjugates is the efficient conjugation of the
photosensitiser to the antibody. The majority of current strategies
for conjugation involve the use of photosensitisers bearing an
activated ester functionality for conjugation to free amines within
the MAb structure (Vrouenraets et al, 1999). Typically, photo-
sensitisers in clinical trials are used. A limitation in such syntheses
is the isolation of photosensitisers containing only one activated
ester. Previously a derivative of meta-tetrahydroxyphenyl chlorin
(m-THPC) has been synthesised bearing four activated esters on
the meta positions of the meso phenyl rings. The monoesterified
compound was then accessed through hydrolysis of this inter-
mediate. However, the kinetics of the reaction are difficult to
control and appreciable amounts of the fully hydrolysed and
therefore unreactive photosensitiser are generated, as well as
photosensitiser bearing two reactive esters (Vrouenraets et al,
1999). These impurities affect the stoichiometry of further
reactions, and multiple reactive sites can cause antibody cross-
linking during conjugation, leading to reduced yields and
increasing aggregate formation, which can lead to nonspecific
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suptake. Alternatively, syntheses describing the activation of the
carboxyl groups of monoaspartyl chlorin e6 (Npe6), often in
conjunction with the use of polymeric carrier molecules, have been
reported (Goff et al, 1991; Hamblin et al, 1996). The MAb and
photosensitiser are attached to the carrier molecule, which usually
acts to increase both photosensitiser loading and conjugate
solubility. The photosensitiser is often used without purification
and contains three carboxyl groups that may be functionalised,
which could lead to crosslinking of the antibody or polymer. The
use of a polymeric carrier may also affect the photophysics of the
photosensitiser and can lead to nonspecific uptake.
In consideration of the above limitations, we have recently
developed a series of porphyrin photosensitisers bearing a single
reactive isothiocyanate group for conjugation to biomolecules
(Clarke and Boyle, 1999; Sutton et al, 2002). Facile conjugation
to bovine serum albumin was demonstrated with minimal non-
specific binding (Sutton et al, 2002). We now report the use of
photosensitiser isothiocyanates for conjugation to MAb. The
previously developed photosensitisers were conjugated to MAb
35A7, FSP 77 and 17.1A. Monoclonal antibody 35A7 recognises
and binds to carcinoembryonic antigen (CEA), which is over-
expressed on colon adenocarcinomas and represents an antigen
that is not internalised upon MAb binding. FSP 77 binds to the
extracellular domain of the erb-B2 receptor, a receptor widely
expressed on breast and ovarian cancers. The EpCAM epithelial
antigen, to which MAb 17.1A binds, is upregulated in a variety of
malignancies including colorectal carcinoma. FSP 77 and 17.1A are
internalised following antigen binding. The conjugates were
characterised in vitro and in vivo, and their potential for use in
PIT in vitro was assessed using the SKOv3-CEA-1B9 cell line,
which has been previously engineered to express both the CEA and
erb-B2 antigens (Carcenac et al, 2001). Using this, we were able to
compare directly the efficacy of the internalising conjugates with
those that remain surface bound.
These data highlight the versatility of the isothiocyanate group,
which allows conjugation to MAb without the generation of
multiple reactive sites or in situ reactive intermediates. The
enhanced cell killing efficiency of the internalising conjugates is
also demonstrated, suggesting that such molecules should be the
focus of future PIT studies.
MATERIALS AND METHODS
Photosensitisers
The two water-soluble photosensitisers 5-(4-isothiocyanatophe-
nyl)-10,15,20-tri-(3,5-dihydroxyphenyl)porphyrin (1) and 5-(4-
isothiocyantophenyl)-10,15,20-tris-(4-N-methylpyridiniumyl)por-
phyrin trichloride (2) (Figure 1) were synthesised as described
previously (Sutton et al, 2002). Briefly, condensation of 4-
acetamidobenzaldehyde with either 3, 5-dimethoxybenzaldehyde
or pyridine 4-carboxaldehyde under Adler–Longo conditions gave
the corresponding monoacetamido porphyrins, following chroma-
tographic separation. Subsequent acid hydrolysis yielded the
analogous monoamino derivatives. Demethylation of the methoxy
functionalities of porphyrin 1 using boron tribromide gave the
hexa-hydroxylated analogue, which was subsequently treated with
1, 10-thiocarbonyldi-2, 20-pyridone (TDP) to yield the isothiocya-
nate. Porphyrin 2 was reacted with TDP to generate the
isothiocyanate functionality prior to quaternisation with methyl
iodide and anion exchange. The photosensitisers were rigorously
purified following each synthetic step and stored at  201C under a
nitrogen atmosphere until further use.
Monoclonal antibodies
The murine MAb 35A7 and FSP 77 (both IgG1) have been used
previously for conjugation to tetrasulphonato aluminium phtha-
locyanine using the in situ generation of an active ester (Carcenac
et al, 1999). MAb 35A7 binds to an epitope on CEA, which is
overexpressed on foetal colon and colon adenocarcinomas (Khare
et al, 2001). MAb FSP 77 binds to the extracellular domain of the
erb-B2 receptor; this antigen is overexpressed on breast and
ovarian cancers (Cuello et al, 2001). The MAb 17.1A (IgG2a; a
generous gift from Professor S. Warnaar) is an anti-EpCAM
antibody that has also been used previously as the targeting
component of a photosensitiser immunoconjugate, which recog-
nises a commonly overexpressed antigen on colorectal cancers that
is internalised on binding (Hamblin et al, 2000).
Radiolabelling and preparation of conjugates
The intact MAb 35A7 and FSP 77 were radioiodinated using the
Iodogen method (1, 3, 4, 6-tetrachloro-3a,6 a-diphenylglycoluryl,
Sigma, Poole, UK) to arrive at a final specific activity of 0.1mCi of
125Io r1 mCi
131I per mg of protein (1mCi¼37kBq). Free
radioiodine was separated from the MAb on a Sephadex G25
column (Amersham Biosciences, Uppsala, Sweden) eluting with
0.5 M sodium bicarbonate buffer (pH 9.2).
To a 1ml solution of MAb, at a concentration of 1mgml
 1 in
0.5 M bicarbonate buffer (pH 9.2), was added photosensitiser (PS) 1
in DMSO (50ml) or PS 2 in H2O (50ml). The photosensitisers were
added separately at varying concentrations of either 20, 40 or
60mol of photosensitiser per mole of MAb. The reaction vessels
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Figure 1 Chemical structure of porphyrin isothiocyanates.
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swere agitated gently at room temperature for 1h and protected
from light. The conjugates were purified using Sephadex
G25 columns (Amersham Biosciences, Uppsala, Sweden) equili-
brated and eluted with PBS. The number of moles of photo-
sensitiser conjugated per mole of antibody (degree of labelling,
DOL) was calculated by spectroscopy. Briefly, the number of
moles of photosensitiser per conjugate was calculated thus:
Cphotosensitiser¼A420nm/e. The MAb concentration (mgml
 1) was
calculated using: MAb conc (mgml
 1)¼A280nm/1.3. This then
allowed calculation of the number of moles of MAb per conjugate.
The DOL was derived for each conjugate at all the initial molar
ratios employed by division of the moles of photosensitiser by the
moles of MAb.
Cell lines
The LS174T human colon carcinoma cell line to which MAb 35A7
binds, SKOv3 human ovarian carcinoma cell line that MAb FSP 77
binds to and the hybrid cell line SKOv3-CEA-1B9 were available in
our laboratories. The cell lines were grown under standard culture
conditions. Cell lines were grown as monolayers at 371Ci na n
environment containing 5% CO2 in RPMI 1640 (Roswell Park
Memorial Institute). This culture medium was supplemented with
10% (vv
 1) foetal calf serum (FCS), 2mML-glutamine, 100mgml
 1
streptomycin, 100mgml
 1 penicillin and 0.25mgml
 1 amphoter-
icin B (Gibco, Paisley, UK). Cells were subcultured regularly to
ensure exponential growth. The human colorectal adenocarcinoma
cell line Colo 320 (European Collection of Animal and Cell
Cultures) was used in studies involving MAb 17.1A. The cells were
grown in RPMI supplemented with 10% (vv
 1) FCS, 2nML -
glutamine, 100mgml
 1 streptomycin and 100mgml
 1 penicillin.
Animals and tumour model
For experiments involving MAb 35A7, the human colon carcinoma
cell line LS174T was implanted subcutaneously into the hind legs
of Swiss nude mice (CRLC, Montpellier, France). SKOv3 cells were
injected subcutaneously into the same animal model for studies
using the MAb FSP 77. Mice were maintained and handled in
accordance with the recommendations of the local animal care
committee. The animals were allowed free access to food and
water. All the in vivo experiments were performed in compliance
with the French guidelines for experimental animal studies
(Agreement No. B 34-172-27) and fulfil the UKCCCR guidelines
for the welfare of animals in experimental neoplasia.
Flow cytometry
Cells were removed from culture flasks with 5mM EDTA in PBS.
After washing cells were counted, resuspended in PBS/0.25%
(wv
 1) BSA and 2 10
5 cells were added to each tube. The cells
were labelled with 50ml( 5 mgml
 1) of primary antibody (con-
jugated/unconjugated/irrelevant) for 1h at 41C. After washing with
PBS/0.25% (wv
 1) BSA, cells were labelled with 50ml (10mgml
 1)
of rabbit anti-mouse IgG–FITC (Serotec, Oxford, UK) for 1h at
41C. A further wash with PBS/0.25% (wv
 1) BSA was performed
before analysis of cells on a FACSCalibur flow cytometer (BD
Biosciences, Oxford, UK).
In vitro phototoxicity
This procedure was employed for analysis of the cytotoxicity of the
conjugates of MAb 35A7 and FSP 77 using the SKOv3-CEA-1B9 cell
line, and the conjugates of MAb 17.1A using the Colo 320 cell line.
Cells in logarithmic growth phase were harvested and their
concentration adjusted to 1 10
6 cellsml
 1. They were then
incubated for 24h in the dark with photosensitiser or conjugate at
varying concentrations in the absence of serum. Following
incubation, the cells were washed with DMEM (to eliminate
unbound photosensitiser), resuspended and plated (8000
cellswell
 1) in quadruplicate into a 96-well plate. The plate was
then irradiated with 10Jcm
 2 of cooled and filtered red light
(630nm) delivered by a Patterson light system (Phototherapeutics
Ltd, Albringham, UK: Patterson Lamp BL1000A, bandpass
630715nm filter). After irradiation, 5ml of FCS was added to
each well and the plates (both irradiated and non-irradiated as a
dark toxicity control) were incubated overnight.
The tetrazolium salt 3-4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide (MTT) assay was performed 18–24h post-
irradiation. Briefly, 10ml of MTT solution (5mgml
 1 PBS, MTT
Thiazoyl blue, Sigma Cat. No. M-5655) was added to each well. The
plates were then returned to the incubator for 4h or until sufficient
colour developed. When this was accomplished, 150mlo f
isopropanol-HCl (0.04 N) was added to each well to stop the
reaction. The cells were lysed mechanically, and the blue formazan
crystals produced by the mitochondria of living cells were
dissolved by vigorous pipetting. The plates were then read at
570nm using a Bio-Tek Elx 800 plate reader. The percentage of cell
survival was calculated in proportion to the number of cells
incubated without photosensitiser.
In vitro binding
To measure the in vitro binding and nonspecific binding of the
radiolabelled conjugates of MAb 35A7 and FSP 77, purified antigen
(CEA or erb-B2) was used immobilised on sepharose. The
procedure was performed in quadruplicate. An irrelevant sepha-
rose-bound antigen (Px) was used to assay any non-specific
antigen binding of the conjugates. Consequently, 1mg of purified
sepharose-bound antigen was added per tube. A control tube
containing sepharose without antigen was used in each experiment
to assay any non-specific binding to the sepharose alone. To each
of these tubes was added 20ng of either conjugate or unconjugated
antibody as a 200ml solution of BSA–PBS buffer containing 1%
(vv
 1) normal mouse serum. The total radioactivity of each tube
was measured for 1min. The tubes were then incubated overnight
at room temperature with gentle agitation. After incubation, the
tubes were washed with 2ml BSA–PBS (1mgml
 1) and centri-
fuged for 5min at 3000r.p.m. The supernatant was removed by
aspiration and the washing procedure repeated. Once complete,
the radioactivity of the tubes was again measured for 1min.
The percentage in vitro binding or nonspecific binding was cal-
culated using the following equation: percentage binding¼(g after
incubation/g before incubation) 100.
In vivo biodistribution
Biodistribution studies were performed in Swiss nude mice bearing
subcutaneously implanted xenograft (LS174T and SKOv3). At 24h
before injection, 0.5ml of pure Lugol’s iodine solution was added
to the drinking water to block the thyroid glands of the mice. A
mixture of
125I (conjugates) and
131I (unconjugated Mab) (each at a
specific radioactivity of 1mCi/10mg MAb) was intravenously
injected into three mice per group when the tumours had reached
a diameter of 3–5mm. At 24h after injection, the mice were killed
by CO2 inhalation. Each mouse was dissected and the organs, body
parts and blood placed in separate preweighed tubes. All the tubes
were weighed separately before and after the addition of the body
parts and the difference between empty and filled tubes calculated.
The
125I and
131I radioactivities of each tube were measured in a
dual-channel scintillation counter (Cobra II auto-gamma, Pack-
ard).
131I activity (14%) was subtracted from
125I radioactivity to
compensate for overlap of
131I-g-rays in the
125I window. Radio-
activity levels are expressed as the percent of injected dose per
gram of tissue (% IDg
 1). The tumour-to-normal tissue ratios
were also calculated.
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sRESULTS
Conjugation and flow cytometric analysis of conjugate
binding
The two photosensitisers were conjugated to MAb 35A7, FSP 77
and 17.1A as described, using an initial molar ratio of 20. The
purified conjugates had a DOL between 1.5 and 2.0. Following
conjugation, the reactivity of the MAb–porphyrin conjugates was
compared to that of the unconjugated MAb using the appropriate
antigen-positive cell lines by flow cytometry (Figure 2).
The binding of the conjugates prepared using MAb 35A7 and
FSP 77 were analysed using the SKOv3-CEA-1B9 cell line. This cell
line had originally been engineered from the erb-B2-expressing cell
line SKOv3 to simultaneously express CEA as well as erb-B2
(Carcenac et al, 2001). The conjugates prepared using MAb 17.1A
were evaluated using the Colo 320 cell line. The conjugate binding
(dotted lines) to the respective cell lines is comparable to that of
the unconjugated MAb (dashed lines) for each MAb and cell line
employed. Conjugating PS 1 and PS 2 to MAb 35A7 and FSP 77
resulted in slightly diminished binding to the SKOv3-CEA-1B9 cell
line (top four histograms), although the conjugates displayed
positive binding with respect to the irrelevant control. The FSP
77–PS 1 conjugate displayed a more pronounced loss of binding,
although it was still positive with respect to the control. No
apparent loss of binding was observed using the conjugates of
MAb 17.1A on Colo 320 cells.
In vitro cytotoxicity
The photocytotoxicity of the photosensitisers and conjugates was
assayed by the MTT assay using the SKOv3-CEA-1B9 cell line
(35A7 and FSP 77) and the Colo 320 cell line (17.1A). Use of
SKOv3-CEA-1B9 cells allowed direct comparison between inter-
nalising and non-internalising conjugates on the same cell line.
The IC50 values for the photosensitisers and conjugates were
measured to allow for comparative assessment of the effects of
MAb conjugation on phototoxicity and are presented in Tables 1
and 2. The photosensitisers and conjugates were not toxic to the
cell lines in the absence of light (data not shown).
The PS 1–17.1A conjugate caused almost five times more cell
growth inhibition than the free photosensitiser. However, coupling
PS 2 to the MAb inhibited cell growth by 90% at a concentration of
only 2.2mM, in comparison to the free photosensitiser, which
required 29.0mM to cause just 50% cell growth inhibition. The non-
internalising PS 1–35A7 conjugate was less effective against the
SKOv3-CEA-1B9 cell line than the free photosensitiser. In contrast,
the internalising PS 1–FSP 77 conjugate gave an IC50 value 15-fold
less than that of the free photosensitiser. A similar trend is
observed with the conjugates of PS 2, although both the conjugates
in this case were more phototoxic than the unconjugated
photosensitiser. Again, the internalising PS 2–FSP 77 conjugate
led to greater cell growth inhibition, having an IC50 value five-fold
lower than the non-internalising conjugate and 14 times less than
the free photosensitiser. Overall, conjugating the photosensitisers
to MAb increases their potential for PIT in vitro, although
internalising conjugates are clearly the most efficient.
Increased loading ratios and in vitro antigen binding
Having established a protocol for conjugating photosensitiser
isothiocyanates to MAb, demonstrated retention of MAb binding
by FACS and enhanced photodynamic efficiency in vitro, the effect
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Figure 2 Indirect flow cytometric analysis of conjugate binding (bold, irrelevant control; dashed, unconjugated MAb; dotted, porphyrin conjugates).
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sof increasing the porphyrin loading of the MAb was examined to
see if more potent derivatives could be constructed. The conjugates
were then characterised further in an in vivo biodistribution study.
Since limited quantities of MAb 17.1A were available and MAb FSP
77 represents an MAb that binds to an internalising receptor, the
study was completed using only MAb 35A7 and FSP 77. To allow
for comparative biodistribution studies using the MAb conjugates
and unconjugated antibody, the antibodies were radiolabelled with
either
125I (conjugates) or
131I (unconjugated antibodies). Repeat
conjugations were performed using initial molar ratios of 20, 40
and 60 and the conjugates were purified as before. The overall DOL
of the antibodies with the photosensitisers was measured spectro-
scopically and is presented in Table 3.
Increasing the initial molar ratio generally led to minor
increases in the DOL of the conjugates with photosensitiser.
However, the DOL of the PS 1–FSP 77 conjugate decreased as the
initial molar ratio increased. This was thought to be a consequence
of the photosensitiser diminishing the solubility of the MAb in PBS
at higher loading ratios. This also corresponded to a reduced
recovery of the conjugate from the Sephadex G25 column, an effect
that has been reported elsewhere (Vrouenraets et al, 2000). The
conjugates synthesised using PS 2 and MAb 35A7 were recovered
quantitatively. Clearly, when conjugating PS 1 with MAb FSP 77 at
initial molar ratios of 40 and 60, only the least substituted MAb is
soluble enough to pass through the column.
The immunoreactivity of the conjugates in vitro was compared
to that of the unconjugated antibodies in a direct binding assay
using CEA and erb-B2 immobilised on sepharose. An irrelevant
antigen (Px) was used to assay any nonspecific binding. The
conjugate binding to the respective antigens was not statistically
different to that of the unconjugated antibodies (data not shown)
and the nonspecific binding was less than 5% in each case.
In vivo biodistribution
For biodistribution analysis of the
131I-MAb 35A7 and
125I-MAb
35A7–porphyrin conjugates, the LS174T cell line was subcuta-
neously implanted into the hind legs of Swiss nude mice. To assay
the biodistribution of the
125I-MAb FSP 77 conjugates and
131I-
labelled free antibody, SKOv3 cells were injected into the
hindquarters of the same animal model. The biodistribution of
the conjugates of each photosensitiser at differing degrees of
labelling was compared to that of the unconjugated antibody for
each conjugate subset. Figure 3 shows the biodistribution profile
for the PS 1–35A7 conjugate at different DOL. The biodistribution
of each conjugate was compared to the unconjugated antibody in
each experiment. The % IDg
 1 tumour and tumour-to-normal
tissue ratios for representative peritumoral tissues for all the
conjugates at each DOL are shown in Tables 4 and 5. The
conjugates prepared using PS 1 have tumour uptake values
comparable to those of the unconjugated MAb 35A7 (Figure 3) and
FSP 77. Increasing the DOL of the conjugates using PS 2 is
associated with a decreased uptake in tumour, in comparison to
the unconjugated MAb. For example, using PS 2–35A7 conjugates
with DOL of 1.6, 2.3 and 2.5 gave tumour uptake values of 23.9,
17.4 and 12.9% IDg
 1 tissue, respectively.
Concurrent with biodistribution studies using a similar photo-
sensitiser (Vrouenraets et al, 2000), it is evident that increased
loading with PS 2 decreases the residence time of the MAb in the
blood, resulting in reduced tumour uptake. The tumour-to-normal
tissue ratios for the MAb 35A7 conjugates are significantly higher
than those observed using the MAb FSP 77 conjugates. The
tumour/blood ratios for the MAb 35A7 conjugate are moderate but
similar to values reported elsewhere (Carcenac et al, 1999). The
values for the MAb FSP 77 conjugates are slightly lower. This may
reflect an increased MAb to tumour transport time using this
antibody. Overall, the ratios for both antibody conjugates were still
significantly higher than typical ratios reported using common
photosensitisers (Boyle and Dolphin, 1996). Tumour-to-colon
ratios for the PS 1–35A7 (DOL, 2.0) and PS 2–35A7 (DOL, 1.6)
conjugates were 33.3 and 33.5, respectively. Since the conjugates
are directed against CEA, which is overexpressed on colorectal
cancers in comparison to that on normal tissues, these values
suggest the potential for more selective photosensitiser delivery to
this tumour type.
DISCUSSION
The use of MAb to increase the specificity of photosensitisers for
malignant tissues was first reported by Mew et al (1983).
Alternative methods of conjugating to MAb using better defined
photosensitisers and polymeric carriers were subsequently devel-
oped (Jiang et al, 1990; Goff et al, 1991). However, these conjugate
preparations often contained significant amounts of impurities. A
more refined method for conjugation to polymeric cationic and
anionic carriers was later developed by Hamblin et al (1996) and
was used successfully in vitro (Del Governatore et al, 2000) and in
vivo (Duska et al, 1997). Within these studies, a chlorin e6-NHS
ester is used without purification prior to attachment to the
macromolecule. Also polycationic macromolecules can increase
the rate of nonspecific cell-mediated endocytosis (Shen and Ryser,
1978). Other methodologies, also relying on activated ester groups,
Table 1 IC50 values (mM) for the free PS 1 and PS 2 and MAb–17.1A
conjugates to the Colo 320 cell line
IC50 value
PS 1 11.572.1
PS 1–17.1A 2.50
a
PS 2 29.074.2
PS 2–17.1A 2.2
a,b
MAb¼monoclonal antibodies; PS¼photosensitisers. Values expressed as the
mean7s.d. of three experiments.
aS.d. could not be determined in these cases
due to the limited availability of MAb 17.1A.
bLD90 value.
Table 2 IC50 values (mM) for the free PS 1 and PS 2 and MAb conjugates
to the SKOv3-CEA-1B9 cell line
IC50 value
PS 1 68.0718.0
PS 1–35A7 No IC50
PS 1–FSP 77 4.270.9
PS 2 24.072.1
PS 2–35A7 10.073.0
PS 2–FSP 77 1.771.1
MAb¼monoclonal antibodies; PS¼photosensitisers. Values expressed as the
mean7s.d. of three experiments.
Table 3 MAb–PS conjugate DOL at differing initial molar ratios
MAb 35A7 MAb FSP 77
DOL
Initial molar ratio PS 1 PS 2 PS 1 PS 2
20 1.4 1.6 2.8 1.6
40 1.6 2.3 2.3 2.0
60 2.0 2.5 1.6 2.0
MAb¼monoclonal antibodies; DOL¼degree of labeling; % IDg
 1¼percent of
injected dose per gram of tissue; PS¼photosensitisers.
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shave involved direct attachment of the photosensitiser to the MAb
(Vrouenraets et al, 1999, 2001). The photosensitisers m-THPC and
[AlPc(SO3H)]4 with a trifluorophenyl (TFP)-ester group were
obtained by hydrolysis of the corresponding tetra-TFP-ester
intermediates. However, the procedure led to preparations
containing appreciable amounts of fully hydrolysed by product.
Savellano and Hasan (2003) later developed a purified mono-
functionalised BPD-MA derivative and used a 50% DMSO/50%
water system for conjugation. This procedure yielded well-
characterised conjugates, although the solvent system is unlikely
to be universally tolerated by MAb.
In the present study, we have investigated the use of
photosensitiser isothiocyanates for conjugation to MAb. The
photosensitisers were synthesised according to a previously
published method (Clarke and Boyle, 1999). This synthesis yields
pure photosensitiser, which unambiguously presents a single
amino reactive group. Efficient conjugation to BSA, with negligible
non-specific binding, has been previously demonstrated (Sutton
et al, 2002). In a continuation of the study, the photosensitisers
were conjugated with MAb 35A7, FSP 77 and 17.1A. Conjugations
were performed under ambient conditions and the procedure
allowed direct attachment of the photosensitisers to the MAb, with
no prior modification of the antibodies. In this context, the
isothiocyanate group represents a superior functionality for
conjugation of photosensitisers to MAb. Retention of antigen
binding was demonstrated using flow cytometry. The in vitro
photoinduced cell inhibition of the conjugates was compared to
the unconjugated photosensitisers. Conjugation to MAb 17.1A led
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Figure 3 Biodistribution of unconjugated MAb control (open bars) and PS 1–35A7 conjugate at the following DOL: 1.4 (black bars), 1.6 (grey bars), 2.0
(crossed bars). Tu, tumour; Li, liver; Ki, kidney; Lu, lungs; Sp, spleen; He, heart; Mu, muscle; Bo, bone; Sk, skin; St, stomach; Si, small intestine; Co, colon; Ca,
carcass; Bl, blood. The values were obtained 24h postinjection. Values are expressed as the mean7s.d. calculated from the three mice bearing the LS174T
xenograft in each conjugate group. The conjugates were compared to unconjugated MAb in three separate experiments.
Table 4 %I Dg
 1 of tumour and tumour/normal tissue ratios for MAb 35A7 conjugates
Ratio
Conjugate+DOL % IDg
 1 tumour Tumour/blood Tumour/muscle Tumour/colon Tumour/small int.
PS 1 (1.4) 17.371.1 1.170.1 15.670.7 22.171.7 16.771.3
PS 1 (1.6) 23.3712.8 1.570.7 16.8710.0 29.4715.9 18.8712.3
PS 1 (2.0) 31.8777.0 1.870.1 18.572.8 33.375.0 23.073.2
PS 2 (1.6) 23.973.4 2.170.2 24.973.4 33.573.8 26.375.2
PS 2 (2.3) 17.476.2 1.970.7 19.876.0 25.1710.3 14.8712.2
PS 2 (2.5) 12.974.2 1.970.6 16.675.6 18.775.3 13.474.7
%I Dg
 1¼percent of injected dose per gram of tissue; MAb¼monoclonal antibodies; DOL¼degree of labeling; PS¼photosensitisers. Values were obtained 24h postinjection
(values are the means of tumour/normal ratios and % IDg
 1 tumour7s.d. calculated from the three mice bearing the LS174T xenograft in each conjugate group).
Table 5 %I Dg
 1 of tumour and tumour/normal tissue ratios for MAb FSP 77 conjugates
Ratio
Conjugate+DOL % IDg
 1 tumour Tumour/blood Tumour/muscle Tumour/colon Tumour/small int.
PS 1 (2.8) 6.474.7 0.670.1 6.170.4 9.170.4 7.270.6
PS 1 (2.3) 7.472.2 0.670.2 5.670.2 10.672.7 5.372.2
PS 1 (1.6) 6.870.2 0.970.7 3.3572.8 7.570.3 3.7572.2
PS 2 (1.6) 8.572.1 1.0670.1 9.276.3 13.878.7 10.776.4
PS 2 (2.0) 5.370.2 0.670.2 5.270.5 8.674.1 5.670.9
PS 2 (2.0) 4.270.1 0.670.1 4.470.4 7.070.5 5.570.1
%I Dg
 1¼percent of injected dose per gram of tissue; MAb¼monoclonal antibodies; DOL¼degree of labeling; PS¼photosensitisers. Values were obtained 24h postinjection
(values are the means of tumour/normal ratios and % IDg
 1 tumour7s.d. calculated from the three mice bearing the SKOv3 xenograft in each conjugate group).
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sto a significant decrease in the concentration of photosensitiser
required for growth inhibition of the Colo 320 cell line as
compared with free photosensitiser. Comparative analysis of the
non-internalising 35A7 conjugates and the internalising FSP 77
conjugates was performed using the SKOv3-CEA-1B9 cell line. The
non-internalising conjugates using MAb 35A7 were generally more
effective than the free photosensitiser and the internalising MAb
FSP 77 conjugates were significantly more active than the 35A7
conjugates or the free photosensitiser. The PS 1–FSP 77 conjugate
gave an IC50 value 16 times less than that of the unconjugated
photosensitiser. Concurrent with results from previous studies
(Carcenac et al, 2001), the use of internalising MAb in PIT offers
advantages over conjugates of non-internalising MAb or free
photosensitisers.
Radiolabelled conjugates were then prepared for use in in vivo
biodistribution studies. MAb 35A7 and FSP 77 were chosen to
represent MAb that are non-internalising and internalising,
respectively. The biodistribution of the
125I-labelled conjugates
was then compared to that of the
131I-labelled MAb in Swiss nude
mice subcutaneously implanted with the appropriate antigen-
expressing cell lines. The MAb conjugates with PS 1 had
biodistribution values comparable to the unconjugated antibodies.
A high uptake in the blood was observed with MAb FSP 77. The
least substituted conjugates of PS 2 and the two MAb had tumour
uptake values similar to the unconjugated antibodies. When the
substitution of the MAb with the photosensitiser increased, the
uptake in the tumour and other organs decreased significantly.
This is consistent with a report by Pardridge et al (1998) who
found that increasing an MAb cationic charge reduced its serum
half-life to 5% of that of the unmodified antibody. The data from
the biodistribution studies clearly demonstrates retention of MAb
pharmacokinetics following substitution with PS 1 and to a lesser
degree with PS 2. The observed tumour/normal tissue ratios using
representative surrounding tissue for colon carcinomas were
exceptionally high at 33.5 for the MAb 35A7 PS 2 conjugate.
Tumour/normal tissue ratios between 2 and 4 have previously been
reported for unconjugated photosensitisers (Boyle and Dolphin,
1996). Indeed, if tumour/normal tissue ratios could be significantly
improved, PDT may play an important role in destroying early
stage metastasis after surgical resection of large tumour masses. In
conclusion, we have developed a convenient and widely applicable
strategy for the conjugation of photosensitisers to antibodies that
offers several advantages over methods currently employed for
conjugation. The conjugates retained antigen binding and had
pharmacokinetics comparable to the unconjugated antibodies. The
use of conjugates of internalising antibodies offered clear
advantages over free photosensitisers in PIT studies in vitro,i n
terms of both specificity and cytotoxicity, and hold promise for
clinical use. Experiments assessing the phototoxicity of the
conjugates in vivo are currently underway in our laboratories.
ACKNOWLEDGEMENTS
We wish to thank the Wellcome Trust (059572, 066948), BBSRC
(21/E12509) and The Leverhume Trust (F/00181H) for financial
support. RH thanks EPSRC for a studentship. The authors wish to
thank Huguette Savoie for expert technical assistance.
REFERENCES
Biel MA (1998) Photodynamic therapy and the treatment of head and neck
neoplasia. Laryngoscope 108: 1259–1267
Boyle RW, Dolphin D (1996) Structure and biodistribution relationships of
photodynamic sensitizers. Photochem Photobiol 64: 469–485
Brasseur N, Langlois R, Madeleine CL, Ouellet R, van Lier JE (1999)
Receptor-mediated targeting of phthalocyanines to macrophages via
covalent coupling to native or maleylated bovine serum albumin.
Photochem Photobiol 69: 345–352
Carcenac M, Dorvillius M, Garambois V, Glaussel F, Larroque C, Langlois
R, Hynes NE, van Lier JE, Pelegrin A (2001) Internalisation enhances
photo-induced cytotoxicity of monoclonal antibody–phthalocyanine
conjugates. Br J Cancer 85: 1787–1793
Carcenac M, Larroque C, Langlois R, van Lier JE, Artus J-C, Pelegrin A
(1999) Preparation, phototoxicity and biodistribution studies of anti-
carcinoembryonic antigen monoclonal antibody-phthalocyanine. Photo-
chem Photobiol 70: 930–936
Clarke OJ, Boyle RW (1999) Isothiocyanatoporphyrins, useful intermedi-
ates for the conjugation of porphyrins with biomolecules and solid
supports. Chem Commun 2231–2232
Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis
PA, Lipkowitz S (2001) Down-regulation of the erbB-2 Receptor by
trastuzumab (Herceptin) enhances tumor necrosis factor-related apop-
tosis-inducing ligand-mediated apoptosis in breast and ovarian cancer
cell lines that overexpress erbB-2. Cancer Res 61: 4892–4900
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan
J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90: 889–905
Duska LR, Hamblin MR, Bamberg MP (1997) Biodistribution of charged
F(ab0)2 photoimmunoconjugates in a xenograft model of ovarian cancer.
Br J Cancer 75: 837–844
Gijsens A, Missiaen L, Merlevede W, de Witte P (2000) Epidermal growth
factor-mediated targeting of chlorin e6 selectively potentiates its
photodynamic activity. Cancer Res 60: 2197–2202
Goff BA, Bamberg M, Hasan T (1991) Photoimmunotherapy of human
ovarian carcinoma cells ex vivo. Cancer Res 51: 4762–4767
Del Governatore M, Hamblin MR, Piccinini EE, Ugolini G, Hasan T (2000)
Targeted photodestruction of human colon cancer cells using charged
17.1A chlorin e6 conjugates. Br J Cancer 82: 56–64
Hamblin MR, Del Governatore M, Rizvi I, Hasan T (2000) Biodistribution
of charged 17.1A photoimmunoconjugates in a murine model of hepatic
metastasis of colorectal cancer. Br J Cancer 83: 1544–1551
Hamblin MR, Miller JL, Hasan T (1996) Effect of charge on the interaction
of site-specific photoimmunoconjugates with human ovarian cancer
cells. Cancer Res 56: 5205–5210
Jiang FN, Jiang S, Liu D, Richter A, Levy JG (1990) Development of
technology for linking photosensitizers to a model monoclonal antibody.
J Immunol Methods 134: 139–149
Khare PD, Shao-Xi L, Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita
Y, Kuroki M (2001) Specifically targeted killing of carcinoembryonic
antigen (CEA)-expressing cells by a retroviral vector displaying single-
chain variable fragmented antibody to CEA and carrying the gene for
inducible nitric oxide synthase. Cancer Res 61: 370–375
Kubler AC, Haase T, Staff C, Kahle B, Rheinwald M, Muhling J (1999)
Photodynamic therapy of primary nonmelanomatous skin tumours of
the head and neck. Lasers Surg Med 25: 60–68
Macdonald IJ, Dougherty TJ (2001) Basic Principles of Photodynamic
Therapy. J Porphyrins Phthalocyanines 5: 105–129
Mew D, Wat CK, Towers GHN, Levy JG (1983) Photoimmunotherapy:
treatment of animal tumours with tumour-specific monoclonal anti-
body–hematoporphyrin conjugates. J Immunol 130: 1473–1477
Nseyo UO, Shumaker B, Klein EA, Sutherland K (1998) Photodynamic
therapy using porfimer sodium as an alternative to cystectomy in
patients with refractory transitional cell carcinoma in situ of the bladder.
J Urol 160: 39–44
Pardridge WM, Buciak J, Yang J, Wu D (1998) Enhanced endocytosis in
cultured human breast carcinoma cells and in vivo biodistribution in rats
of a humanized monoclonal antibody after cationization of the protein.
J Pharmacol Exp Ther 286: 548–554
Savellano MD, Hasan T (2003) Targeting cells that overexpress the
epidermal growth factor receptor with polyethylene glycolated BPD
verteporfin photosensitizer immunoconjugates. Photochem Photobiol 77:
431–439
Shen WC, Ryser HJ (1978) Conjugation of poly-L-lysine to albumin and
horse radish peroxidase: a novel method of enhancing the cellular uptake
of proteins. Acad Sci USA 75: 1872–1876
Antibody conjugates for photoimmunotherapy
R Hudson et al
1448
British Journal of Cancer (2005) 92(8), 1442–1449 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sSutton JM, Clarke OJ, Fernandez N, Boyle RW (2002) Porphyrin,
chlorin, and bacteriochlorin isothiocyanates: useful reagents for
the synthesis of photoactive bioconjugates. Bioconjugate Chem 13:
249–263
Swamy N, James DA, Mohr SC, Hanson RN, Ray R (2002) An estradiol–
porphyrin conjugate selectively localizes into estrogen receptor-positive
breast cancer cells. Bioorg Med Chem 10: 3237–3243
Vrouenraets MB, Visser GWM, Loup C, Meunier B, Stigter M, Oppelaar H,
Stewart FA, Snow GB, van Dongen GAMS (2000) Targeting of a
hydrophilic photosensitizer by use of internalizing monoclonal anti-
bodies: a new possibility for use in photodynamic therapy. Int J Cancer
88: 108–114
Vrouenraets MB, Visser GWM, Stewart FA, Stigter M, Oppelaar H, Postmus
PE, Snow GB, van Dongen GAMS (1999) Development of meta-
tetrahydroxyphenylchlorin–monoclonal antibody conjugates for photo-
immunotherapy. Cancer Res 59: 1505–1513
Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB, van
Dongen GAMS (2001) Targeting of aluminium (III) phthalocyanine
tetrasulfonate by use of internalizing monoclonal antibodies: improved
efficacy in photodynamic therapy. Cancer Res 61: 1970–1975
Antibody conjugates for photoimmunotherapy
R Hudson et al
1449
British Journal of Cancer (2005) 92(8), 1442–1449 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s